Date: 2012-01-23
Type of information: Granting of a patent
Product name: MOR202
Compound: MOR202 (anti CD38 antibody)
Therapeutic area: Cancer - Oncology - Rare diseases
Action mechanism: monoclonal antibody. MOR202 is a fully human HuCAL antibody directed against CD38, a therapeutic target for the treatment of multiple myeloma and certain forms of leukemia. The HuCAL-derived, fully human antibody is currently being tested in a phase 1-2a trial in patients with relapsed/refractory myeloma.
Company: Morphosys (Germany)
Disease:
Latest news:
Patents: * On January 23, 2011, MorphoSys announced that the US Patent and Trademark Office (USPTO) has granted a patent covering the cancer compound MOR202. The new patent (US 8,088,896) covers MorphoSys\'s HuCAL antibody against CD38 as well as pharmaceutical compositions comprising the same, and has a scheduled expiry date in 2028, not including any potential regulatory extensions.
* On December 6, 2012, MorphoSys has announced that the USPTO has granted a patent covering MOR202. The new patent (US 8,263,746) covers functional properties of anti-CD38 antibodies and provides additional patent protection for MorphoSys\'s HuCAL antibody MOR202. The new patent has a scheduled expiry date in 2025, not including any potential patent office or regulatory extensions.
Submission of marketing authorization application USA :
Submission of marketing authorization application UE:
Withdrawal of marketing authorization application USA:
Withdrawal of marketing authorization application UE:
US authorization:
UE authorization:
Favourable opinion UE:
Favourable opinion USA:
Orphan status USA:
Orphan status UE:
Pediatric exclusivit _USA:
Pediatric exclusivity UE: OTC status: Other news:
